Central Pattern Generator - start up funding for Ceryx Medical Ltd

Project: Research council

Description

£500k from InnovateUK 64912-260142, April 2016 - March 2018
Matching funds from:
£50k from Bath Crescent fund
£250k from the Bristol Research and Enterprise fund

Layman's description

Novel Bioelectronic Technology with Physiological Feedback for the Treatment of Cardiorespiratory Disease
Public Description of Project
With the current boom in medical devices to treat diseases, we have entered an era of “bioelectronic” medicine. Bioelectronic therapies are free from the side effects of drugs; they target diseases better than drugs and often provide the only way to restore neurological and cardiorespiratory functions. With 0.6M pacemakers implanted each year worldwide, the cardiac rhythm management (CRM) market is growing at a rate of 3-4% per annum and is expected to reach $11bn in 2015. Most chronic diseases, however, have treatments which are only appropriate for a tiny minority of patients. These diseases include congestive heart failure (0.9M patients in UK; 4.8M/USA), traumatic spinal cord/brain injury (1.4M/USA), Parkinson’s disease (1M/USA), essential tremor (1.5M/USA), dystonia (0.25M/USA), epilepsy (3M/USA), Alzheimer (5.4M/USA) and chronic migraine (3.2M/USA). Their debilitating and life-threatening effects create an urgent need to find novel bioelectronics solutions.
Bioelectronics research creates major opportunities for pharmaceutical companies who are increasingly diversifying away from drugs (GlaxoWellcome $50M bioelectronic challenge). The Central Pattern Generator (CPG) implants, which we are developing, introduce the type of disruptive science and technology which is needed to effectively cure chronic diseases, improve the life of patients, relieve the burden on medical carers and National Health resources, and to gain insights into the pathology of chronic diseases. Although the technology has a wide range of applications, it will be developed initially to specifically to restore cardiac function in heart failure with indirect benefits for hypertensive and sleep apnoea patients. The advantages of neural bioelectronics include an ability to integrate in real time biological inputs and synchronize to physiological feedback with the effect of increased efficacy, safety and autonomy for the patient. The technology also provides resilience to electromagnetic noise (in MRI scans), non-invasiveness, design simplicity, increased miniaturization, and longer battery life.
Short title£800k
StatusFinished
Effective start/end date1/04/1631/03/18